Applying ACC/AHA 2025 guidelines instead of ESH 2023 criteria to Polish adults increased hypertension prevalence (75.4% vs 53.6%) without significantly changing drug treatment recommendations.
Cross-Sectional (n=1,439)
Does the application of ACC/AHA 2025 guidelines compared to ESH 2023 guidelines change the prevalence of hypertension and treatment recommendations in Polish adults aged 40-79?
Applying ACC/AHA 2025 guidelines in Poland would significantly increase the diagnosed prevalence of hypertension compared to ESH 2023 guidelines, primarily driving nonpharmacological preventive measures rather than drug therapy.
Absolute Event Rate: 75.4% vs 53.6%
Objective: Assessment of arterial hypertension (AH) prevalence and control based on ESH (European Society of Hypertension) 2023 and ACC/AHA (American College of Cardiology/American Heart Association) 2025 guidelines using database of the national survey in Poland as country representing Central Eastern Europe.Design and method: We examined the prevalence of hypertension and the proportion of individuals recommended for pharmacological therapy in accordance with the ESH 2023 and the ACC/AHA 2025 guidelines. The database of national cross-sectional survey NATPOL 2011 that we used comprised a representative random sample of 1439 Polish adults aged 40 to 79. Blood pressure (BP) measurements were performed in each subject three times during two separate visits. The results were weighted to reflect the structure of the population in Poland and were stratified by age and gender. In analyses, we followed specialized algorithms to diagnose hypertension and cvd risk according to ESH 2023 and ACC/AHA 2025 criteria. For treatment recommendations based on the American guidelines, the PREVENT algorithm was employed. Results: The overall prevalence of hypertension among Polish adults aged 40-79 according to the ACC/AHA guideline was 75.4% (CI 72.4-78.2%) versus 53.6% (CI 49.8-57.4%) according to the ESH guidelines. On the other hand, application of the ACC/AHA recommendations would result in antihypertensive drug treatment for 58,8% (CI 54,8–62,7%) of Polish adults compared with 55.4% (CI 51.7-59.0%) based on the ESH guidelines (NS)(Table 1). Conclusions: In summary, the ACC/AHA guidelines would result in a substantial increase in the prevalence of hypertension and in the number of individuals targeted for preventive measures and nonpharmacological therapy.
Szczesny et al. (Fri,) conducted a cross-sectional in Arterial hypertension (n=1,439). ACC/AHA 2025 guidelines vs. ESH 2023 guidelines was evaluated on Prevalence of hypertension. Applying ACC/AHA 2025 guidelines instead of ESH 2023 criteria to Polish adults increased hypertension prevalence (75.4% vs 53.6%) without significantly changing drug treatment recommendations.